Synapse - Works

Results (13087)

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial

Meeting Abstract

Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yanez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies

Meeting Abstract

Rodríguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J. W.; Hassoun, H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM)

Meeting Abstract

Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Liu, F.; Liao, K. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)

Meeting Abstract

Carvajal, R. D.; Sato, T.; Butler, M. O.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Rioth, M.; Hamid, O.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US)

Meeting Abstract

Jacobson, C. A.; Locke, F. L.; Hu, Z. H.; Siddiqi, T.; Ahmed, S.; Ghobadi, A.; Miklos, D. B.; Lin, Y.; Perales, M. A.; Lunning, M. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Overall survival benefit from tebentafusp in patients with best response of progressive disease

Meeting Abstract

Joshua, A. M.; Baurain, J. F.; Piperno-Neumann, S.; Nathan, P.; Hassel, J. C.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)

Meeting Abstract

Sato, T.; Carvajal, R. D.; Sacco, J. J.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L. F.; Nathan, P.; Rioth, M.; Hamid, O.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma

Meeting Abstract

Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24)

Meeting Abstract

Jacobson, C. A.; Chavez, J. C.; Sehgal, A.; William, B. M.; Munoz, J.; Salles, G. A.; Casulo, C.; Munshi, P. N.; Maloney, D. G.; De Vos, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON)

Meeting Abstract

Cortes, J. E.; Apperley, J.; Lomaia, E.; Moiraghi, B.; Sutton, M. U.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; Schiffer, C.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save